BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PMV Pharmaceuticals\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies PMV Pharmaceuticals\, Inc's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04585750-2704@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:rezatapopt: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:rezatapopt\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a
  TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0458575
 0
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
